Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108


Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking.

Andres F, Iamele L, Meyer T, Stüber JC, Kast F, Gherardi E, Niemann HH, Plückthun A.

J Mol Biol. 2019 May 3;431(10):2020-2039. doi: 10.1016/j.jmb.2019.03.024. Epub 2019 Mar 28.


Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging.

Duranti C, Carraresi L, Sette A, Stefanini M, Lottini T, Crescioli S, Crociani O, Iamele L, De Jonge H, Gherardi E, Arcangeli A.

Oncotarget. 2018 Oct 9;9(79):34972-34989. doi: 10.18632/oncotarget.26200. eCollection 2018 Oct 9.


Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain.

DiCara DM, Chirgadze DY, Pope AR, Karatt-Vellatt A, Winter A, Slavny P, van den Heuvel J, Parthiban K, Holland J, Packman LC, Mavria G, Hoffmann J, Birchmeier W, Gherardi E, McCafferty J.

Sci Rep. 2017 Aug 21;7(1):9000. doi: 10.1038/s41598-017-09460-2.


Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach.

Winter A, Sigurdardottir AG, DiCara D, Valenti G, Blundell TL, Gherardi E.

Mol Cancer Ther. 2016 Jan;15(1):3-14. doi: 10.1158/1535-7163.MCT-15-0446. Epub 2015 Dec 28.


Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding.

Sigurdardottir AG, Winter A, Sobkowicz A, Fragai M, Chirgadze D, Ascher DB, Blundell TL, Gherardi E.

Chem Sci. 2015 Nov 1;6(11):6147-6157. doi: 10.1039/c5sc02155c. Epub 2015 Jul 31.


Crystal structure of an engineered YopM-InlB hybrid protein.

Breitsprecher D, Gherardi E, Bleymüller WM, Niemann HH.

BMC Struct Biol. 2014 Mar 27;14:12. doi: 10.1186/1472-6807-14-12.


Engineered variants of InlB with an additional leucine-rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complex.

Niemann HH, Gherardi E, Bleymüller WM, Heinz DW.

Protein Sci. 2012 Oct;21(10):1528-39. doi: 10.1002/pro.2142. Epub 2012 Sep 17.


Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG.

PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12.


Targeting MET in cancer: rationale and progress.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G.

Nat Rev Cancer. 2012 Jan 24;12(2):89-103. doi: 10.1038/nrc3205. Review. Erratum in: Nat Rev Cancer. 2012 Sep;12(9):637.


Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver.

Ross J, Gherardi E, Mallorqui-Fernandez N, Bocci M, Sobkowicz A, Rees M, Rowe A, Ellmerich S, Massie I, Soeda J, Selden C, Hodgson H.

Gastroenterology. 2012 Apr;142(4):897-906. doi: 10.1053/j.gastro.2011.12.006. Epub 2011 Dec 13.


Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.

Sinha Roy R, Soni S, Harfouche R, Vasudevan PR, Holmes O, de Jonge H, Rowe A, Paraskar A, Hentschel DM, Chirgadze D, Blundell TL, Gherardi E, Mashelkar RA, Sengupta S.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13608-13. doi: 10.1073/pnas.1006007107. Epub 2010 Jul 16.


Structural basis for agonism and antagonism of hepatocyte growth factor.

Tolbert WD, Daugherty-Holtrop J, Gherardi E, Vande Woude G, Xu HE.

Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13264-9. doi: 10.1073/pnas.1005183107. Epub 2010 Jul 12.


Glycoprotein production for structure analysis with stable, glycosylation mutant CHO cell lines established by fluorescence-activated cell sorting.

Wilke S, Krausze J, Gossen M, Groebe L, Jäger V, Gherardi E, van den Heuvel J, Büssow K.

Protein Sci. 2010 Jun;19(6):1264-71. doi: 10.1002/pro.390.


Ligand-mediated dimerization of the Met receptor tyrosine kinase by the bacterial invasion protein InlB.

Ferraris DM, Gherardi E, Di Y, Heinz DW, Niemann HH.

J Mol Biol. 2010 Jan 22;395(3):522-32. doi: 10.1016/j.jmb.2009.10.074. Epub 2009 Nov 6.


A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Vande Woude G, Cao B.

Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):57-67. doi: 10.1097/PAI.0b013e3181816ae2.


Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist.

Youles M, Holmes O, Petoukhov MV, Nessen MA, Stivala S, Svergun DI, Gherardi E.

J Mol Biol. 2008 Mar 28;377(3):616-22. doi: 10.1016/j.jmb.2008.01.034. Epub 2008 Jan 18.


X-ray and neutron small-angle scattering analysis of the complex formed by the Met receptor and the Listeria monocytogenes invasion protein InlB.

Niemann HH, Petoukhov MV, Härtlein M, Moulin M, Gherardi E, Timmins P, Heinz DW, Svergun DI.

J Mol Biol. 2008 Mar 21;377(2):489-500. doi: 10.1016/j.jmb.2008.01.027. Epub 2008 Jan 16.


Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density.

Catlow KR, Deakin JA, Wei Z, Delehedde M, Fernig DG, Gherardi E, Gallagher JT, Pavão MS, Lyon M.

J Biol Chem. 2008 Feb 29;283(9):5235-48. Epub 2007 Dec 21.


A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.

Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Vande Woude G, Xu HE.

Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14592-7. Epub 2007 Sep 5.


Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB.

Niemann HH, Jäger V, Butler PJ, van den Heuvel J, Schmidt S, Ferraris D, Gherardi E, Heinz DW.

Cell. 2007 Jul 27;130(2):235-46.


Eotaxin-1/CC chemokine ligand 11: a novel eosinophil survival factor secreted by human pulmonary artery endothelial cells.

Farahi N, Cowburn AS, Upton PD, Deighton J, Sobolewski A, Gherardi E, Morrell NW, Chilvers ER.

J Immunol. 2007 Jul 15;179(2):1264-73.


Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.

Holmes O, Pillozzi S, Deakin JA, Carafoli F, Kemp L, Butler PJ, Lyon M, Gherardi E.

J Mol Biol. 2007 Mar 23;367(2):395-408. Epub 2007 Jan 26.


Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors.

Kemp LE, Mulloy B, Gherardi E.

Biochem Soc Trans. 2006 Jun;34(Pt 3):414-7. Review.


Structural basis of affinity maturation of the TEPC15/Vkappa45.1 anti-2-phenyl-5-oxazolone antibodies.

Scotti C, Gherardi E.

J Mol Biol. 2006 Jun 23;359(5):1161-9. Epub 2006 May 2.


Structural basis of hepatocyte growth factor/scatter factor and MET signalling.

Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, Svergun DI.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4046-51. Epub 2006 Mar 6.


Computer-assisted mass spectrometric analysis of naturally occurring and artificially introduced cross-links in proteins and protein complexes.

de Koning LJ, Kasper PT, Back JW, Nessen MA, Vanrobaeys F, Van Beeumen J, Gherardi E, de Koster CG, de Jong L.

FEBS J. 2006 Jan;273(2):281-91.


Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis.

McKinnon H, Gherardi E, Reidy M, Bowyer D.

Am J Pathol. 2006 Jan;168(1):340-8.


Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein.

Carafoli F, Chirgadze DY, Blundell TL, Gherardi E.

FEBS J. 2005 Nov;272(22):5799-807.


Nitric oxide modulates hepatocyte growth factor/scatter factor-induced angiogenesis.

Sengupta S, Sellers LA, Gherardi E, Sasisekharan R, Fan TP.

Angiogenesis. 2004;7(4):285-94. Epub 2005 May 9.


The sema domain.

Gherardi E, Love CA, Esnouf RM, Jones EY.

Curr Opin Struct Biol. 2004 Dec;14(6):669-78. Review.


Diverse and potent activities of HGF/SF in skin wound repair.

Bevan D, Gherardi E, Fan TP, Edwards D, Warn R.

J Pathol. 2004 Jul;203(3):831-8.


Met, metastasis, motility and more.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.

Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25. Review. No abstract available.


Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.

Sengupta S, Sellers LA, Cindrova T, Skepper J, Gherardi E, Sasisekharan R, Fan TP.

Cancer Res. 2003 Dec 1;63(23):8351-9.


Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.

Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, Bandyopadhyay A, Hartmann G, Butler PJ.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12039-44. Epub 2003 Oct 3.


A G2/M cell cycle block in transformed cells by contact with normal neighbors.

Allard D, Stoker M, Gherardi E.

Cell Cycle. 2003 Sep-Oct;2(5):484-7.


Aromatic amino acids at the surface of InlB are essential for host cell invasion by Listeria monocytogenes.

Machner MP, Frese S, Schubert WD, Orian-Rousseau V, Gherardi E, Wehland J, Niemann HH, Heinz DW.

Mol Microbiol. 2003 Jun;48(6):1525-36.


Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis.

Sengupta S, Sellers LA, Li RC, Gherardi E, Zhao G, Watson N, Sasisekharan R, Fan TP.

Circulation. 2003 Jun 17;107(23):2955-61. Epub 2003 Jun 2.


Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor.

Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TP.

Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):69-75.


A new crystal form of the NK1 splice variant of HGF/SF demonstrates extensive hinge movement and suggests that the NK1 dimer originates by domain swapping.

Watanabe K, Chirgadze DY, Lietha D, de Jonge H, Blundell TL, Gherardi E.

J Mol Biol. 2002 May 31;319(2):283-8.


Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling.

Lindner G, Menrad A, Gherardi E, Merlino G, Welker P, Handjiski B, Roloff B, Paus R.

FASEB J. 2000 Feb;14(2):319-32.


Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.

van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST.

J Biol Chem. 1999 Mar 5;274(10):6499-506.


Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding.

Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, Gherardi E.

Nat Struct Biol. 1999 Jan;6(1):72-9.


Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.

Birchmeier C, Gherardi E.

Trends Cell Biol. 1998 Oct;8(10):404-10. Review.


Insights into the structure of hepatocyte growth factor/scatter factor (HGF/SF) and implications for receptor activation.

Chirgadze DY, Hepple J, Byrd RA, Sowdhamini R, Blundell TL, Gherardi E.

FEBS Lett. 1998 Jun 23;430(1-2):126-9. Review.


Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo.

Hartmann G, Prospero T, Brinkmann V, Ozcelik C, Winter G, Hepple J, Batley S, Bladt F, Sachs M, Birchmeier C, Birchmeier W, Gherardi E.

Curr Biol. 1998 Jan 29;8(3):125-34. Erratum in: Curr Biol 1998 Oct 8;8(20):R739. Ozcelik O [corrected to Ozcelik C].


Supplemental Content

Loading ...
Support Center